NCT05689827View on ClinicalTrials.gov

Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
AstheniaCOVID-19
Interventions
DRUG

Ethyl methyl hydroxypyridine succinate + Meldonium

Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)

DRUG

Placebo

Placebo was used in the same way

Trial Locations (6)

Unknown

"Federal State Budgetary Research Institution Research Centre of Neurology", Moscow

OsteoVita LLC, Saint Petersburg

"Saint Petersburg State Budgetary Healthcare Institution Municipal Hospital No. 40 of Kurortny District", Sestroretsk

Centre For Evidence-Based Medicine Llc, Yaroslavl

Medical Centre of Diagnostics and Prevention Plus LLC, Yaroslavl

"State Budgetary Healthcare Institution of Yaroslavl Region Yaroslavl Region Clinical Hospital for War Veterans - International Elderly People Centre 'Zdorovoe Dolgoletie'", Yaroslavl

All Listed Sponsors
lead

Promomed, LLC

OTHER